Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

CJC-1295 No DAC Dosing Protocol: 5 mg Vial — Pulsatile GHRH +

CJC-1295 No DAC 5 mg vial: 2 mg/mL, 300 μg (15 units) 2–3x daily with GHRP. Mix-in-syringe guide. Reviewed Feb 2026. Reviewed Feb 2026.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

CJC-1295 No DAC Dosing Protocol: 5 mg Vial — Pulsatile GHRH Dosing Guide

CJC-1295 without DAC (Modified GRF 1-29) protocol — the pulsatile GHRH analogue for 2–3x daily injection alongside GHRPs.

Quickstart highlights

CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) is a 29-amino acid GHRH analogue with four amino acid substitutions (Ala8, Glu15, Ala18, Arg26) that improve receptor affinity and proteolytic stability over native GHRH while maintaining a physiological 30-minute half-life.

Concentration: 2 mg/mL (5 mg vial + 2.5 mL bacteriostatic water).

At 2 mg/mL: 200 μg = 10 units, 300 μg = 15 units per injection.

Half-life: ~30 minutes — inject simultaneously with GHRP (ipamorelin, GHRP-2) for synergistic GH release.

Can be mixed with ipamorelin or GHRP-2 in the same syringe immediately before injection.

One 5 mg vial provides ~17 doses at 300 μg — approximately 5–6 days at 3x daily.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

1-4

200

10

1–2x daily with GHRP

200 μg — 10 units; pair with ipamorelin or GHRP-2 (200 μg) in same syringe or adjacent site

5-12

300

15

2–3x daily with GHRP

300 μg — 15 units; 3x daily protocol produces maximum pulsatile GH output

Your free CJC-1295 No DAC tracker

Dose reminders

Injection logging

Cycle progress

Reconstitution steps

Draw 2.5 mL bacteriostatic water; inject slowly down the vial wall.

Swirl gently until powder dissolves; do not shake.

Final concentration: 2 mg/mL (2,000 μg/mL). At 2 mg/mL: 200 μg = 10 units, 300 μg = 15 units.

Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

4-week plan

2 vials

28 syringes

5 mL bac water

28 alcohol swabs

8-week plan

4 vials

56 syringes

10 mL bac water

56 alcohol swabs

12-week plan

5 vials

84 syringes

13 mL bac water

84 alcohol swabs

Protocol overview & cycle notes

Achieve maximal pulsatile GH secretion through the precise co-injection of CJC-1295 No DAC (GHRH) and a GHRP (ipamorelin or GHRP-2) 2–3x daily, mimicking the natural GHRH + ghrelin synergy that drives physiological GH pulses.

Cycle length: 12 weeks on.

Off-cycle: 4–6 weeks off; measure IGF-1 before resuming.

Storage & handling

Injection & tracking tips

CJC-1295 No DAC has a 30-minute half-life — timing with the GHRP injection is critical; inject within 5 minutes of each other.

Can be mixed in the same syringe as ipamorelin or GHRP-2 for a single injection — stable when mixed immediately before use; do not pre-mix and store.

Inject in fasted state (2+ hours post-meal); food-driven insulin blunts GH response to the peptide combination.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

Measure IGF-1 at baseline, 6 weeks, and 12 weeks.

Track sleep quality nightly (subjective 0–10 or wearable deep sleep data).

Log body fat percentage monthly via InBody or DEXA.

How this works & references

Sources

Source: Bowers CY — Unnatural GH-releasing peptides beget natural ghrelin. J Clin Endocrinol Metab. 2001

Source: Ghigo E et al. — GH-releasing peptide-6: hypothalamic or pituitary site of action? J Clin Endocrinol Metab. 1993

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Teichman SL et al. — J Clin Endocrinol Metab — 2006

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Sackmann-Sala L et al. — Growth Horm IGF Res — 2009

Frequently asked questions

Related protocols

KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide

KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.

GLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide

GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Connected topics

Follow this recovery question